Who
Lori Anne Kunkel
Director
Company insider
Files Form 4 as: Director, Enliven Therapeutics; Director, Oric Pharmaceuticals; Director, Nurix Therapeutics; Director, Curis; Acting-Chief Medical Officer, Forte Biosciences; Director, Loxo Oncology; Chief Medical Officer, Pharmacyclics.
In numbers
- Trades disclosed
- 89
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $11.5M
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 1 Dec 2011
- Last trade
- 6 Jul 2026
- Last filed
- 8 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Jul 2026filed 8 Jul 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $205K4,111 at $49.98 | filing |
| 6 Jul 2026filed 8 Jul 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $299K5,889 at $50.84 | filing |
| 6 Jul 2026filed 8 Jul 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $205K4,111 at $49.98 | filing |
| 6 Jul 2026filed 8 Jul 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $299K5,889 at $50.84 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $267K7,779 at $34.28 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $66K1,867 at $35.36 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $13K354 at $35.82 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $267K7,779 at $34.28 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $66K1,867 at $35.36 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $13K354 at $35.82 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,126 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,126 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 17 Dec 2025filed 19 Dec 2025 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,958 at $0.00 | filing |
| 17 Dec 2025filed 19 Dec 2025 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code M | $18K15,958 at $1.12 | filing |
| 8 Dec 2025filed 9 Dec 2025 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 8 Dec 2025filed 9 Dec 2025 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $79K10,000 at $7.90 | filing |
| 4 Dec 2025filed 5 Dec 2025 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,534 at $0.00 | filing |
| 4 Dec 2025filed 5 Dec 2025 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $21K5,534 at $3.75 | filing |
News
Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearELVN · prnewswire.com · 14 Oct 2026Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid LeukemiaELVN · prnewswire.com · 6 Oct 2026
0 headlines in the last 90 days name Lori Anne Kunkel; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.